Skip to main content
Premium Trial:

Request an Annual Quote

Nucleonics Adds $8.3M to Series B Funding

NEW YORK, June 2 (GenomeWeb News) - Nucleonics has added a second capital infusion to Series B funding first closed in March, the Malvern, Pa.-based RNAi company said yesterday.


New investor Quaker BioVentures of Philadelphia participated in the $8.3 million second close, joining previous investors New Enterprise Associates of Baltimore, and SR One of West Conshohocken, Pa., to bring the round to $49.2 million, following a $40.9 million first close in March.


The 12-employee firm, which, according to RNAi News, GenomeWeb's sister publication, was founded in 2001 to commercialize gene-silencing technology developed by the company's founders while they were scientists at Apollon, is currently developing an RNAi-based treatment for hepatitis B, which is expected to be ready for phase I testing as early as the first quarter next year. The firm's technical approach is to use DNA plasmids that have been designed to express long pieces of double-stranded RNA targeting multiple genomic sequences.


The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.